Gland Pharma Intrinsic Value
GLAND Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹981.20 | ₹784.96 - ₹1177.44 | -42.1% | EPS: ₹44.60, Sector P/E: 22x |
| Book Value Method | asset | ₹4237.00 | ₹3813.30 - ₹4660.70 | +150.0% | Book Value/Share: ₹5382.94, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3389.60 | ₹3050.64 - ₹3728.56 | +100.0% | Revenue/Share: ₹3696.47, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3389.60 | ₹3050.64 - ₹3728.56 | +100.0% | EBITDA: ₹1592.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹4237.00 | ₹3389.60 - ₹5084.40 | +150.0% | CF Growth: 10.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹508.44 | ₹457.60 - ₹559.28 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹689.07 | ₹620.16 - ₹757.98 | -59.3% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹3389.60 | ₹3050.64 - ₹3728.56 | +100.0% | ROE: 8.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹2324.17 | ₹2091.75 - ₹2556.59 | +37.1% | EPS: ₹44.60, BVPS: ₹5382.94 |
Want to compare with current market value? Check GLAND share price latest .
Valuation Comparison Chart
GLAND Intrinsic Value Analysis
What is the intrinsic value of GLAND?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Gland Pharma (GLAND) is ₹3389.60 (median value). With the current market price of ₹1694.80, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹508.44 to ₹4237.00, indicating ₹508.44 - ₹4237.00.
Is GLAND undervalued or overvalued?
Based on our multi-method analysis, Gland Pharma (GLAND) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.23 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 8.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.56x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Gland Pharma
Additional stock information and data for GLAND
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹915 Cr | ₹915 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹997 Cr | ₹123 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹364 Cr | ₹364 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹791 Cr | ₹292 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹605 Cr | ₹-155 Cr | Positive Operating Cash Flow | 6/10 |